CME Group (CME)
Technical, fundamental, and sentiment analysis with recent related videos.
CME rates Neutral overall. The fundamental read is bearish: the company passes 3 of 9 quality tests on the Piotroski F-Score; balance sheet is flagged Distress (Altman Z = 0.59); revenue is growing about 9.1% per year; net income is growing about 14.9% per year. The technical picture is bullish: price is 6.1% above the 200-day moving average; 5.5% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 74/100), based on 6 news articles, 1 TV segment, and 1 qualified video from recent coverage.
Revenue 3-year avg +9.1%. Net income 3-year avg +14.9%.
Price vs 20DMA +3.3%. RSI 58.08. Bollinger state: Inside Bands.
Composite score 74/100 from the AI judge, based on 6 news items, 1 television segments, and 1 videos.
Latest Market Read
Technical and sentiment signals are bullish while the fundamentals badge is bearish, producing an overall Neutral rating. The Fundamental rating reflects the site’s assessment despite revenue averaging 9.1 percent per year and net income averaging 14.9 percent per year over three years. The Technical badge shows price about 3.3 percent above its 20-day moving average (the average closing price over the last 20 trading days), the Relative Strength Index (RSI), a momentum reading, at 58.1, and price inside the Bollinger Bands (the volatility channel). Sentiment is Bullish with a 74/100 composite, but the bearish fundamental label offsets the other two.
Recent news: Global Database of Events, Language, and Tone (GDELT) articles and Internet Archive TV coverage highlight a Zacks upgrade to Buy, TV reports of record third-quarter revenue, CME Group’s push toward 24/7 trading, and a record day in Brazilian real futures, all tied to strong fundamentals (62% net margin, low leverage). Coverage also notes operational limits to full 24/7 adoption, an insider sale, and a planned Dec 7 clearing-agency launch needing regulatory approval; recent videos feature Terry Duffy on regulation and CME-related market themes.